Evidence map›Paper›PMID 41504491›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Spatio-Temporal Proteomic Landscape Reveals Early Warning Signals of Esophageal Squamous Cell Carcinoma Progression.

Xumiao Li, Jie Yuan, Min Gao, Jibin Liu, Qinqin Wang, Yaqi Zhang, Mingtao Cao, Xiaolin Hu, Hui Yang, Jun Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xumiao LiState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jie YuanState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Min GaoState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jibin LiuInstitute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Qinqin WangState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yaqi ZhangState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mingtao CaoState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaolin HuState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hui YangNHC Key Laboratory of Food Safety Risk Assessment, China National Center for Food Safety Risk Assessment, Beijing, China.
Jun LiCancer Prevention and Treatment Office, Yanting Cancer Hospital, Mianyang, China.
Chen LiState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaoguang LiState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hui WangState Key Laboratory of Systems Medicine For Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-2095-690X

Funding

Innovative Research Team of High-level Local University in ShanghaiNational Key R&D Program of China 2022YFD2101500National Natural Science Foundation of China (NSFC) 81972820National Natural Science Foundation of China (NSFC) 82030099National Natural Science Foundation of China (NSFC) 82373446National Natural Science Foundation of China (NSFC) 82574086Science and Technology Commission of Shanghai Municipality 22DZ2303000Shanghai Jiao Tong University Key Program of Medical Engineering YG2021ZD01Shanghai Municipal Science and Technology Commission "Science and Technology Innovation Action Plan" Natural Science Foundation Project 23ZR1435800Shanghai Municipal Science and Technology Commission "Science and Technology Innovation Action Plan" Natural Science Foundation Project 23ZR1435900Shanghai Municipal Science and Technology Commission "Science and Technology Innovation Action Plan" Technical Standard Project (21DZ2201700)Shanghai Public Health System Construction Three-Year Action Plan GWVI-11.1-43
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) remains a lethal malignancy lacking reliable biomarkers for precancerous lesion monitoring and intervention. In this study, formalin-fixed, paraffin-embedded archived tissue biopsies from 134 individuals across two cohorts are collected, spanning five stages of ESCC progression. Laser capture microdissection is employed to isolate the epithelial lesion (L) and the adjacent non-lesion (N) tissues. Proteomic profiling reveals a comprehensive spatio-temporal landscape of ESCC progression, encompassing 4461 proteins. Dynamic network biomarker analysis indicates moderate dysplasia (MOD) as the critical turning stage, warranting clinical attention. A seven-protein diagnostic panel (CCDC86, GBP6, PDCD6IP, C19orf53, SF3A3, GMPPB, ARPC5) with an area under the curve (AUC) of 0.956 achieves superior early detection, and the key signatures are validated by immunohistochemistry in an independent cohort. Functional validation using malignantly transformed HET-1A cells, ESCC cells, and mouse xenograft models identifies GBP6 as a novel target: DNA damage-induced progressive loss of GBP6 promotes ESCC progression by accelerating cell cycle and inducing epithelial-mesenchymal transition. Critically, PARP1 inhibition rescues GBP6 loss by suppressing TP63 and prevents ESCC progression. Overall, this study provides a systematic proteomic atlas of ESCC progression, identifies MOD as a pivotal clinical decision point, and proposes PARP1-TP63-GBP6 axis targeting as a novel intervention strategy.

Indexed as

Biomarkers, TumorEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaProteomicsAnimalsCell Line, TumorDisease ProgressionFemaleHumansMaleMiceBiomarkers, Tumordynamic network biomarkeresophageal squamous cell carcinomaGBP6PARP1spatio‐temporal proteomic landscape

Identifiers

PMID41504491
PMCPMC13042397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.